|
US20020168718A1
(en)
*
|
1997-04-03 |
2002-11-14 |
California Institute Of Technology |
Enzyme-mediated modification of fibrin for tissue engineering
|
|
US7601685B2
(en)
*
|
1998-08-27 |
2009-10-13 |
Eidgenossische Technische Hochschule Zurich |
Growth factor modified protein matrices for tissue engineering
|
|
US6958212B1
(en)
*
|
1999-02-01 |
2005-10-25 |
Eidgenossische Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
|
DK1181323T3
(da)
|
1999-02-01 |
2011-10-17 |
Eidgenoess Tech Hochschule |
Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
|
|
EP1190061A1
(en)
*
|
1999-06-07 |
2002-03-27 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US7291673B2
(en)
*
|
2000-06-02 |
2007-11-06 |
Eidgenossiche Technische Hochschule Zurich |
Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
|
|
EP1465989B1
(en)
*
|
2001-12-18 |
2008-02-20 |
Eidgenossisch Technische Hochschule Zurich |
Growth factor modified protein matrices for tissue engineering
|
|
US7247609B2
(en)
*
|
2001-12-18 |
2007-07-24 |
Universitat Zurich |
Growth factor modified protein matrices for tissue engineering
|
|
ATE386545T1
(de)
*
|
2001-12-18 |
2008-03-15 |
Eth Zuerich |
Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)
|
|
US8282912B2
(en)
*
|
2002-03-22 |
2012-10-09 |
Kuros Biosurgery, AG |
Compositions for tissue augmentation
|
|
US8399400B2
(en)
*
|
2004-12-01 |
2013-03-19 |
Syntaxin, Ltd. |
Fusion proteins
|
|
GB0426394D0
(en)
*
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
|
US8603779B2
(en)
|
2004-12-01 |
2013-12-10 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
US8778634B2
(en)
|
2004-12-01 |
2014-07-15 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
US8512984B2
(en)
|
2004-12-01 |
2013-08-20 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
EP1828244A2
(en)
*
|
2004-12-22 |
2007-09-05 |
Kuros Biosurgery AG |
Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
|
|
SG161218A1
(en)
*
|
2005-01-06 |
2010-05-27 |
Kuros Biosurgery Ag |
Supplemented matrices for the repair of bone fractures
|
|
US8575101B2
(en)
|
2005-01-06 |
2013-11-05 |
Kuros Biosurgery Ag |
Supplemented matrices for the repair of bone fractures
|
|
WO2006073711A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Kuros Biosurgery Ag |
Use of a matrix comprising a contrast agent in soft tissues
|
|
GB0610867D0
(en)
|
2006-06-01 |
2006-07-12 |
Syntaxin Ltd |
Treatment of pain
|
|
CN101711168B
(zh)
|
2007-04-13 |
2013-05-01 |
库罗斯生物外科股份公司 |
聚合物组织封闭剂
|
|
CA2710798A1
(en)
|
2007-12-28 |
2009-07-09 |
Kuros Biosurgery Ag |
Pdgf fusion proteins incorporated into fibrin foams
|
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
|
AU2010296018B2
(en)
*
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
EP2678002A2
(en)
|
2011-02-25 |
2014-01-01 |
Medtronic, Inc. |
Therapy for kidney disease and/or heart failure
|
|
ES2882852T3
(es)
|
2011-03-16 |
2021-12-02 |
Kuros Biosurgery Ag |
Formulación farmacéutica para la utilización en la fusión espinal
|
|
US20130244937A1
(en)
|
2011-09-02 |
2013-09-19 |
Nile Therapeutics, Inc. |
Chimeric natriuretic peptide compositions and methods of preparation
|
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
|
US20140056870A1
(en)
|
2012-08-27 |
2014-02-27 |
Allergan, Inc. |
Fusion proteins
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|